Ginkgo biloba: A Leaf of Hope in the Fight against Alzheimer’s Dementia: Clinical Trial Systematic Review
Guilherme Lopes de Oliveira Pagotto,
Livia Maria Oliveira dos Santos,
Najwa Osman
и другие.
Antioxidants,
Год журнала:
2024,
Номер
13(6), С. 651 - 651
Опубликована: Май 27, 2024
Alzheimer’s
disease
(AD)
is
a
stealthy
and
progressive
neurological
disorder
that
leading
cause
of
dementia
in
the
global
elderly
population,
imposing
significant
burden
on
both
society.
Currently,
condition
treated
with
medications
alleviate
symptoms.
Nonetheless,
these
drugs
may
not
consistently
produce
desired
results
can
serious
side
effects.
Hence,
there
vigorous
pursuit
alternative
options
to
enhance
quality
life
for
patients.
Ginkgo
biloba
(GB),
an
herb
historical
use
traditional
medicine,
contains
bioactive
compounds
such
as
terpenoids
(Ginkgolides
A,
B,
C),
polyphenols,
organic
acids,
flavonoids
(quercetin,
kaempferol,
isorhamnetin).
These
are
associated
anti-inflammatory,
antioxidant,
neuroprotective
properties,
making
them
valuable
cognitive
health.
A
systematic
search
across
three
databases
using
specific
keywords—GB
AD
dementia—yielded
1702
documents,
selection
15
clinical
trials
synthesis.
In
eleven
studies,
GB
extract/EGb
761®
was
shown
improve
function,
neuropsychiatric
symptoms,
functional
abilities
types.
four
however,
were
no
differences
between
GB-treated
placebo
groups.
Significant
improvements
observed
scores
obtained
from
Mini-Mental
State
Examination
(MMSE),
Short
Cognitive
Performance
Test
(SKT),
Neuropsychiatric
Inventory
(NPI).
While
majority
synthesized
show
has
promising
potential
treatment
conditions,
more
research
needed
determine
optimal
dosages,
effective
delivery
methods,
appropriate
pharmaceutical
formulations.
Furthermore,
thorough
assessment
adverse
effects,
exploration
long-term
implications,
investigation
into
drug
interactions
critical
aspects
must
be
carefully
evaluated
future
studies.
Язык: Английский
Limitations of human brain organoids to study neurodegenerative diseases: a manual to survive
Frontiers in Cellular Neuroscience,
Год журнала:
2024,
Номер
18
Опубликована: Июль 9, 2024
In
2013,
M.
Lancaster
described
the
first
protocol
to
obtain
human
brain
organoids.
These
organoids,
usually
generated
from
human-induced
pluripotent
stem
cells,
can
mimic
three-dimensional
structure
of
brain.
While
they
recapitulate
salient
developmental
stages
brain,
their
use
investigate
onset
and
mechanisms
neurodegenerative
diseases
still
faces
crucial
limitations.
this
review,
we
aim
highlight
these
limitations,
which
hinder
organoids
becoming
reliable
models
study
such
as
Alzheimer’s
disease
(AD),
Parkinson’s
(PD),
amyotrophic
lateral
sclerosis
(ALS).
Specifically,
will
describe
structural
biological
impediments,
including
lack
an
aging
footprint,
angiogenesis,
myelination,
inclusion
functional
immunocompetent
microglia—all
important
factors
in
neurodegeneration
AD,
PD,
ALS.
Additionally,
discuss
technical
limitations
for
monitoring
microanatomy
electrophysiology
parallel,
propose
solutions
overcome
current
thereby
making
a
more
tool
model
neurodegeneration.
Язык: Английский
Harnessing the potential of human induced pluripotent stem cells, functional assays and machine learning for neurodevelopmental disorders
Frontiers in Neuroscience,
Год журнала:
2025,
Номер
18
Опубликована: Янв. 8, 2025
Neurodevelopmental
disorders
(NDDs)
affect
4.7%
of
the
global
population
and
are
associated
with
delays
in
brain
development
a
spectrum
impairments
that
can
lead
to
lifelong
disability
even
mortality.
Identification
biomarkers
for
accurate
diagnosis
medications
effective
treatment
lacking,
part
due
historical
use
preclinical
model
systems
do
not
translate
well
clinic
neurological
disorders,
such
as
rodents
heterologous
cell
lines.
Human-induced
pluripotent
stem
cells
(hiPSCs)
promising
vitro
system
modeling
NDDs,
providing
opportunities
understand
mechanisms
driving
NDDs
human
neurons.
Functional
assays,
including
patch
clamping,
multielectrode
array,
imaging-based
popular
tools
employed
hiPSC
disease
models
investigation.
Recent
progress
machine
learning
(ML)
algorithms
also
presents
unprecedented
advance
NDD
research
process.
In
this
review,
we
compare
two-dimensional
three-dimensional
formats
modeling,
discuss
applications
functional
offer
insights
on
incorporating
ML
into
hiPSC-based
drug
screening.
Язык: Английский
Guidelines for Manufacturing and Application of Organoids: Brain
International Journal of Stem Cells,
Год журнала:
2024,
Номер
17(2), С. 158 - 181
Опубликована: Май 23, 2024
Taehwan
Kwak,
Si-Hyung
Park,
Siyoung
Lee,
Yujeong
Shin,
Ki-Jun
Yoon,
Seung-Woo
Cho,
Jong-Chan
Seung-Ho
Yang,
Heeyeong
Heh-In
Im,
Sun-Ju
Ahn,
Woong
Sun,
Ji
Hun
Yang.
IJSC
-0001;0:.
https://doi.org/10.15283/ijsc24056
Organoids of Musculoskeletal System for Disease Modeling, Drug Screening, and Regeneration
Advanced Healthcare Materials,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 28, 2024
Abstract
Musculoskeletal
diseases
have
emerged
as
the
leading
cause
of
disability
worldwide,
with
their
prevalence
increasing
annually.
In
light
this
escalating
health
challenge,
organoids,
an
emerging
technology
in
tissue
engineering,
offer
promising
solutions
for
disease
modeling,
drug
screening,
regeneration,
and
repair
processes.
The
successful
development
musculoskeletal
organoids
represents
a
significant
breakthrough,
providing
novel
platform
studying
facilitating
discovery
new
treatments.
Moreover,
serve
valuable
complements
to
traditional
2D
culture
methods
animal
models,
offering
rich
insights
into
biology.
This
review
provides
overview
organoid
technology,
outlining
construction
processes
various
highlighting
similarities
differences.
Furthermore,
challenges
associated
systems
are
discussed
future
perspectives
offered.
Язык: Английский